![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nervgen Pharma Corporation | TSXV:NGEN | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -2.11% | 2.32 | 2.31 | 2.34 | 2.39 | 2.27 | 2.38 | 73,111 | 20:59:59 |
TORONTO, May 2, 2019 /CNW/ - Bill Radvak, Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. NervGen Pharma Corp. commenced trading on TSX Venture Exchange on March 13, 2019.
SOURCE TMX Group Limited
Copyright 2019 Canada NewsWire
1 Year Nervgen Pharma Chart |
1 Month Nervgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions